Group 1: Market Overview - The A-share market has shown an "orderly progress" this year, with an increase in IPO activity and a normalization of the delisting mechanism [2][6] - As of June 24, 50 companies have successfully listed, raising approximately 37 billion yuan, indicating growth compared to the same period last year [2][4] - 13 companies have been delisted this year, a significant decrease from 53 in the previous year, reflecting a stricter enforcement of delisting regulations [5][6] Group 2: IPO Activity - Companies such as Haiyang Technology, Yingshi Innovation, and Huazhi Jie have recently entered the A-share market, contributing to the active IPO landscape [3][4] - Haiyang Technology, which focuses on nylon 6 products, and Yingshi Innovation, specializing in smart imaging devices, are among the notable IPOs, with Yingshi raising 1.938 billion yuan for its projects [3][4] - The revenue projections for Yingshi Innovation from 2022 to 2024 are 2.041 billion yuan, 3.636 billion yuan, and 5.574 billion yuan, respectively [3] Group 3: Delisting Mechanism - The delisting process has become more routine, with 150 companies receiving ST or *ST warnings this year, indicating a focus on corporate governance and compliance [6][7] - Companies like *ST Jiyuan and Zhonghang Chanyin have faced delisting due to poor performance and non-compliance, highlighting the market's shift towards eliminating "zombie companies" [5][6] - The regulatory environment is evolving, with a push for stricter delisting standards and improved investor protection mechanisms [9] Group 4: Long-term Implications - The orderly progress in the market is expected to optimize resource allocation, directing funds to growth-oriented companies and enhancing support for the real economy [6] - The quality of listed companies is anticipated to improve as low-efficiency firms are eliminated, compelling remaining companies to strengthen compliance and core competitiveness [6] - A cleaner market ecosystem will likely enhance investor confidence and market vitality, supported by a more market-oriented and legal framework [6]

Core Viewpoint - Multiple listed companies in the Shanghai and Shenzhen markets have announced significant developments, including regulatory actions, acquisitions, capital increases, and stock listings, which may present investment opportunities and risks for investors [2]. Regulatory Actions - Jiaying Pharmaceutical is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws, having received a notice of case filing on May 28, 2025 [3]. - *ST Longjin has received a decision from the Shenzhen Stock Exchange to terminate its stock listing, effective June 27, 2025, due to its stock price being below 1 yuan for twenty consecutive trading days [11][12]. Mergers and Acquisitions - ST United plans to acquire 100% of Runtian Industrial through a combination of share issuance and cash payment, aiming to enhance its positioning in the cultural tourism consumption sector [4]. - Longgao Co. is undergoing a restructuring of its controlling shareholder, Longyan Investment Development Group, which will become a wholly-owned subsidiary of the newly established investment development group with a registered capital of 3 billion yuan [6]. Capital Increases - Sanyou Chemical's controlling shareholder plans to increase capital by 100 million yuan in its subsidiary, Sanyou Silicon Industry, through a private agreement, with no changes to the consolidation scope [7]. Stock Listings - Shantui Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries [9]. - Hehe Information intends to issue H-shares and apply for a listing on the Hong Kong Stock Exchange to enhance its global strategy and brand recognition [10]. Share Buybacks and Increases - China Gold's controlling shareholder plans to increase its stake in the company by 168 million to 335 million yuan within 12 months [13]. - Taiji Industry intends to repurchase shares worth 100 million to 120 million yuan, with the repurchased shares to be canceled [14]. Major Contracts - China Energy Construction's subsidiary has won a coal power project contract worth approximately 14.586 billion yuan [15]. - ST Huaxi has signed a significant contract worth about 2.9 billion USD (approximately 20.84 billion yuan) for the restoration of a power plant in Iraq, which represents 80.38% of its latest audited revenue [16].

Group 1 - Jia Ying Pharmaceutical is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, having received a notice of case filing on May 28, 2025 [2] - ST United plans to acquire 100% of Run Tian Industrial through a combination of share issuance and cash payment, with the stock set to resume trading on May 29 [3] - Long Gao Co., Ltd. is undergoing a restructuring of its controlling shareholder, Longyan Investment Development Group, which has established a new investment development group with a registered capital of 3 billion yuan [4] Group 2 - San You Chemical's controlling shareholder intends to inject 100 million yuan into its subsidiary, Tangshan San You Silicon Industry, through a private agreement [5] - ST Ji Pharmaceutical's stock will be delisted on May 29, 2025, due to a continuous closing price below 1 yuan for twenty trading days [6] - Hehe Information plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its global strategy and brand recognition [8] Group 3 - ST Huaxi has signed a significant contract worth approximately 2.9 billion USD (about 20.84 billion yuan) for a project in Iraq, which represents 80.38% of its latest audited revenue [9] - ST Longjin's stock will enter a delisting preparation period starting June 6, 2025, following a decision by the Shenzhen Stock Exchange [10] - Zhenbao Island's wholly-owned subsidiary intends to acquire a 49% stake in its controlling subsidiary, Guizhou Shennong Valley [11]

板块方面，近20个交易日涨幅前五的板块为：种植业林业涨6.18%、美容护理涨5.76%、零售涨5.69%、 贵金属涨3.37%、农产品(000061)加工涨4.44%；跌幅前五的板块为：光伏跌12.25%、医疗服务跌 10.23%、元件跌9.67%、其他电源设备跌9.4%、通信服务跌8.54%。 格隆汇4月30日｜今日A股4月收官，三大指数月线集体收跌，K线均为长下影阴线，其中，上证指数跌 1.7%报3279点，深证成指跌5.75%报9899点，创业板指跌7.4%报1948点。 个股方面，4月涨幅前五的个股为：信凯科技涨183.28%、泰禾股份涨161.34%、联合化学涨159.09%、 首航新能涨137.03%、肯特催化涨136.07%；同期，跌幅前五的个股为：*ST吉药跌77.66%、东方通 (300379)跌73.02%、普利退跌71.89%、*ST汇科跌65.37%、*ST鹏博跌59.74%。(格隆汇) (责任编辑：宋政 HN002) 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考 ...

Core Viewpoint - *ST Dongfang (600811) has received a termination of listing decision from the Shanghai Stock Exchange, with its stock set to be delisted on April 30, 2025, due to a continuous closing price below 1 yuan for 20 trading days [1][2]. Company Summary - *ST Dongfang, officially known as Dongfang Group Co., Ltd., was established in 1992 and is recognized as the first private enterprise in Heilongjiang Province to publicly issue and list stocks. It is also one of the earliest private enterprises in China to undergo shareholding reform and obtain a listing [3]. - The company operates in four major sectors: modern agriculture and health food, finance, port transportation, and new urbanization development [3]. Industry Context - Recently, several companies in the A-share market have faced delisting due to their stock prices falling below 1 yuan. This includes *ST Xulan, *ST Jiayu, *ST Dongfang, *ST Furun, and *ST Jiyao, all of which have triggered the delisting conditions by having closing prices below 1 yuan for 20 consecutive trading days [3]. - Prior to *ST Dongfang, *ST Jiayu received a termination of listing decision from the Shenzhen Stock Exchange on April 25, 2025, for similar reasons [3]. - Other companies, such as *ST Pengbo, have also seen their stock prices drop below 1 yuan, with the latest price reported at 0.65 yuan per share after 9 consecutive trading days below the threshold [3].

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a long-term focus on domestic innovative drugs in the oncology sector and AI medical investment opportunities [2][3]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.16%, outperforming the Wind All A index (1.15%) and the CSI 300 index (0.38%) during the week of April 21-25, 2025 [3][8]. - The upcoming ASCO annual meeting from May 30 to June 3, 2025, is expected to showcase over 70 oral presentations and more than 10 significant studies from domestic innovative drug companies, indicating a growing competitiveness in the oncology field [3][12]. - The Ministry of Industry and Information Technology and six other departments issued a plan for the digital transformation of the pharmaceutical industry from 2025 to 2030, aiming for significant advancements in competitiveness and quality management by 2027 [3][12]. Market Weekly Review - The pharmaceutical and biotechnology sector increased by 1.16%, with notable performances in medical research outsourcing (6.34%) and raw materials (4.72%), while blood products (-3.26%) and vaccines (-6.38%) continued to decline [3][8]. - Individual stock performances included significant gains for Yong'an Pharmaceutical (31.4%), Shuyou Shen (28.4%), and Erkang Pharmaceutical (27.7%), while *ST Jiyuan (-43.2%), Nanhua Biological (-35.3%), and Shuangcheng Pharmaceutical (-27.7%) faced substantial losses [3][11]. Industry News and Key Company Announcements - On April 25, 2025, Kangfang Biotech announced that its drug Aniko® (pembrolizumab injection) received FDA approval for treating recurrent or metastatic nasopharyngeal carcinoma [12]. - The same day, Kangfang Biotech also reported that its PD-1/VEGF bispecific antibody drug Yiwosi (generic name: Yiwosi monoclonal antibody injection) received approval for a new indication in treating advanced or metastatic non-small cell lung cancer [13]. - The report highlights various companies' quarterly performance forecasts, with notable growth in revenue and profit for companies like Aier Eye Hospital and Hengrui Medicine, while others like InnoCare and Watson Bio reported declines [17][18].

Group 1: Economic Performance in Guangdong - In the first quarter of 2025, Guangdong's GDP reached 33,525.51 billion yuan, with a year-on-year growth of 4.1%, an increase of 0.6 percentage points compared to the previous year [1] - The primary industry added value was 934.45 billion yuan, growing by 3.3%; the secondary industry added value was 12,002.53 billion yuan, growing by 3.7%; and the tertiary industry added value was 20,588.53 billion yuan, growing by 4.3% [1] - The service sector emerged as the main growth engine, indicating a robust economic recovery [1] Group 2: Trade Performance in Shenzhen - In March 2025, Shenzhen's total import and export value reached 3,870.5 billion yuan, with a year-on-year growth of 12.3%, outpacing the national growth rate by 6.3 percentage points [2] - Exports amounted to 2,185.3 billion yuan, growing by 8.8%, while imports were 1,685.2 billion yuan, growing by 17.2% [2] - The strong performance in trade reflects Shenzhen's internal growth momentum and resilience against risks [2] Group 3: Employment Situation in Hong Kong - The unemployment rate in Hong Kong for the first quarter of 2025 was 3.2%, unchanged from the previous period, with an underemployment rate of 1.1% [3] - Total employment reached 3.6927 million, a decrease of approximately 16,800 from the previous period, while the total labor force decreased by about 5,800 to 3.8155 million [3] - Economic growth in mainland China and government stimulus measures are expected to support labor demand despite external uncertainties [3] Group 4: Financial Support for SMEs in Macau - The Macau government launched a loan interest subsidy plan for small and medium-sized enterprises (SMEs), effective from April 22, 2025, to April 22, 2026 [4] - Eligible SMEs can apply for interest subsidies on loans up to 5 million Macau patacas, with a maximum subsidy period of three years and an interest rate cap of 4% [4] - This initiative aims to reduce financing costs and alleviate cash flow pressures for SMEs, supporting their stable operations [4] Group 5: Stock Market Performance - On April 22, 2025, the Shenzhen Component Index closed at 9,870.05 points, down by 0.36% [5] - Notable gainers included Meichen Technology, with a price of 1.66 yuan and a rise of 20.29%, and Xincheng Technology, with a price of 16.66 yuan and a rise of 20.03% [6] - Significant decliners included *ST Jiyuan, with a price of 0.24 yuan and a drop of 20.00% [6]

Market Overview - The A-share market showed mixed performance during the week from April 14 to April 19, with the Shanghai Composite Index rising by 1.19%, while the Shenzhen Component Index and the ChiNext Index fell by 0.54% and 0.64% respectively [1] - Major sectors such as telecommunications equipment, real estate, and banking were active, with the four major banks reaching historical highs on Friday [1] Index Performance - On Friday, the Shanghai Composite Index decreased by 0.11% to close at 3277 points, with a trading volume of 380.3 billion yuan [3] - The Shenzhen Component Index increased by 0.23% to 9782 points, with a trading volume of 534.3 billion yuan [3] - The Northbound 20 Index rose by 1.97% to 1329 points, while the ChiNext Index fell by 0.81% to 1009 points [3] Stock Performance - Guoguang Chain led the weekly gainers with a 61.1% increase, marking five consecutive trading days of gains [4] - A total of 22 stocks saw a rise of over 30%, while 11 stocks experienced a decline of over 20%, with *ST Jiyuan leading the losses at a 50.67% drop [4][5] Trading Activity - 80 stocks had a turnover rate exceeding 100%, with Huaguang Source Sea leading at 274.36% [5][6] - The majority of stocks with high turnover rates were from the basic chemicals, retail, and food and beverage sectors [6] Sector Analysis - Real estate, media, and building materials sectors attracted significant capital inflows, while electronics, computers, and machinery sectors faced net sell-offs exceeding 4 billion yuan [8] - Notable net inflows were seen in Shenghong Technology, Hanwha, and Agricultural Bank, with amounts of 1.332 billion yuan, 615 million yuan, and 580 million yuan respectively [8] Financing Activity - Shenghong Technology topped the list for financing net purchases with 929 million yuan, followed by Lixun Precision and Sairis with 506 million yuan and 487 million yuan respectively [10][11] - Major net sell-offs were recorded for Kweichow Moutai, Jiangsu Bank, and COSCO Shipping, with amounts of 513 million yuan, 365 million yuan, and 363 million yuan respectively [11] Institutional Research - A total of 256 listed companies were researched by institutions, with Ninebot Company receiving the most attention from 248 institutions [12][13] - The focus of institutional research remained on sectors such as pharmaceuticals, electronic components, and automotive [12] New Institutional Interests - 80 stocks were newly favored by institutions this week, indicating potential investment opportunities [14]

Core Viewpoint - *ST Dayao (603963.SH) is set to be delisted from the Shanghai Stock Exchange on March 21 due to negative net profit and revenue below 100 million yuan in 2023, marking a significant decline in its financial health since its IPO in 2017 [1][2][4]. Financial Performance - The company's market capitalization is currently 259 million yuan, the lowest among A-share listed companies [2]. - Since its peak revenue of 401 million yuan in 2018, *ST Dayao has experienced a continuous decline in revenue for six consecutive years, dropping below 100 million yuan in 2023 [5]. - The company has reported losses for three consecutive years from 2021 to 2023 [5]. Delisting Circumstances - The Shanghai Stock Exchange has decided to terminate the company's listing without a delisting adjustment period due to its failure to meet financial performance standards [1][4]. - The company has triggered both financial and trading-related delisting criteria, making it one of the few companies in A-share market to face such circumstances [2][4]. - The company’s stock price fell below the 5 billion yuan threshold, leading to a trading-related delisting decision after 20 consecutive trading days of market capitalization below this level [4][6]. Management and Control Issues - The company's controlling shareholder, Yang Junxiang, faced legal issues that hindered his ability to fulfill his duties, impacting the company's management [3][4]. - Following Yang's investigation, his family members took over the management responsibilities, but the company missed its last opportunity for self-rescue [3][4]. Future Outlook - With the new delisting regulations set to take effect in 2025, the revenue threshold for delisting will increase to 300 million yuan, further complicating *ST Dayao's ability to meet compliance standards [6]. - The company is projected to report negative profits and revenues between 62 million to 74 million yuan for 2024, far below the new revenue threshold [6][9].

Investment Rating - The industry rating is maintained at "Overweight" [4] Core Viewpoints - The government work report emphasizes new goals for the pharmaceutical industry, focusing on enhancing basic medical services and promoting the development of traditional Chinese medicine (TCM) [3] - The TCM sector experienced a slight decline of 0.76% last week, with the overall pharmaceutical sector showing a broader pullback [1][4] - The TCM sector's current PE (ttm) is 25.84X, with a PB (lf) of 2.24X, indicating a valuation premium of 105.83% relative to the CSI 300 index [2][4] Market Performance - Last week, the TCM sector reported a slight decline, with the TCM II index closing at 6207.73 points, down 0.76% [1] - The overall pharmaceutical sector saw a decline of 2.72%, with the medical services sector experiencing the largest drop at 7.94% [1] Valuation - The TCM sector's PE (ttm) decreased by 0.23X week-on-week, while the PB (lf) decreased by 0.01X [2] - The TCM sector's PE is at the 24.71% percentile and PB at the 4.63% percentile over the past decade [2] Government Policy Impact - The government aims to enhance the quality and accessibility of healthcare services, which is expected to benefit the TCM industry [3] - The report highlights the importance of integrating TCM into the broader healthcare system, promoting a full industry chain from cultivation to consumption [3] Investment Opportunities - The report suggests that the TCM industry may see opportunities arising from price governance and consumption recovery in 2025 [4] - Key investment themes include price governance, consumption recovery, and state-owned enterprise reform, with a focus on companies with strong R&D capabilities and market share [4][8]